Advocacy

Prolia® Biosimilar Approval Signals Continued Growth in Specialty Biosimilars

Remedy GPO 2026 Mid-Year Update: Celebrating Growth Across Our Network

Reducing Infusion No-Shows and Late Cancellations: Practical Strategies for Specialty Practices to Protect Capacity and Revenue

The Next Front in Drug Pricing: What Medicare Drug Negotiation Means for Buy-and-Bill Infusion Practices

Harnessing Patient Experience Data to Improve Infusion Practice Performance

2026 PBM Formulary Exclusions: What Independent Practices Need to Know About Biosimilars, Net Pricing, and Market Access

The Hidden Financial Risk of Biologic Therapy Volatility in Neurology

Faster Rituximab Infusions in Rheumatology: Evidence Supports Safe, Efficient Care Delivery

Optimizing Infusion Center Capacity in 2026: Strategies to Do More Without Expanding Footprint

Biosimilar Adoption in 2026: What Every Specialty Practice Needs to Know